Sarcome utérin survenant au cours d’une hormonothérapie par tamoxifène. À propos de deux cas
- 12 September 2001
- journal article
- research article
- Published by Elsevier in La Revue de Médecine Interne
- Vol. 22 (9) , 881-885
- https://doi.org/10.1016/s0248-8663(01)00440-4
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Surveillance for Endometrial Cancer in Women Receiving TamoxifenAnnals of Internal Medicine, 1999
- Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control studyInternational Journal of Cancer, 1998
- A realistic clinical perspective of tamoxifen and endometrial carcinogenesisEuropean Journal Of Cancer, 1996
- Second Cancers After Adjuvant Tamoxifen Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 1996
- Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Mullerian tumor) of the uterus?International Journal of Gynecologic Cancer, 1995
- Tamoxifen Use in Breast Cancer Patients Who Subsequently Develop Corpus Cancer Is Not Associated with a Higher Incidence of Adverse Histologic FeaturesGynecologic Oncology, 1994
- Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *JNCI Journal of the National Cancer Institute, 1994
- Risk of endometrial cancer after tamoxifen treatment of breast cancerThe Lancet, 1994
- PELVIC IRRADIATION AND TAMOXIFEN AS RISK FACTORS FOR CARCINOMA OF CORPUS UTERIThe Lancet, 1988
- TAMOXIFEN AS RISK FACTOR FOR CARCINOMA OF CORPUS UTERIThe Lancet, 1988